RxDoctor Payments DataLook up a doctor →

Craig Petry, MD

Family Medicine · Lynchburg, VANPI 1285657213

Payments from drug & device makers

$19,495in general payments, 2019–2025

Across 626 payments — averaging $31.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$11K
  • Novo Nordisk$2K
  • Johnson & Johnson$2K
  • Musculoskeletal Transplant Foundation Inc.$1K
  • Pfizer$360
  • Amgen$322
  • plus $2K from 32 others

What the payments were for

  • Speaking & faculty fees$8,00041%
  • Travel & lodging$1,5278%
  • Food & beverage$9,96351%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,495 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$141,734
Medicare patients
391
Services billed
5,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$58,732
XareltoRivaroxaban32$29,107
OzempicSemaglutide19$29,093
MounjaroTirzepatide13$16,702
Atorvastatin Calcium245$1,524
Rosuvastatin Calcium119$1,394
Fenofibrate46$940
Levothyroxine Sodium82$753
Febuxostat13$736
Amlodipine Besylate68$694
Montelukast Sodium76$681
Pantoprazole Sodium39$665
Metformin Hcl102$648
Lisinopril94$626
Omeprazole70$572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$26$58,73249 claims
Johnson & JohnsonXarelto$1,732$29,10732 claims
Novo NordiskOzempic$2,075$29,09319 claims
Lilly USA, LLCMounjaro$261$16,70213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →